Northwest Biotherapeutics has applied for approval to market DCVax®, a personalized immune therapy, for the treatment of Glioblastoma.

Gleolan is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.

The End Brain Cancer Initiative (EBCI) and I are once again thrilled to have this platform to increase patient education, awareness & outreach to the global brain tumor community and to the general public with the goal of increasing their direct access to top brain tumor specialists at brain tumor centers of excellence, multiple treatment options/diagnostics and clinical trials.

PROSPECT is an open-label, Phase II study evaluating the efficacy, safety, and pharmacokinetics of an investigational oral medicine called Tirabrutinib (ONO-4059), for patients with primary central nervous system lymphoma (PCNSL).

Your support is essential to ensuring that the unmet needs of the brain tumor community continue to be heard and addressed. Together, we can advocate for patients and families today, while fueling research with the potential to become the treatments and cures of tomorrow.

Imaging Biometrics (IB) has been developing imaging analysis software for primary brain tumors for close to 30 years. Recently, their imaging software was used to assess treatment response in a pre-clinical study of Gallium Maltolate.

This month’s CURE MAG Cover Tip brought to you by the End Brain Cancer Initiative (EBCI) and through our patient advocacy and disease education partnership with CURE, focuses on turning Glioblastoma Multiforme (GBM) from a deadly disease into a chronic managed disease.

This month’s Advocacy & Disease Education Cover Tip is shedding a light on a neuro-surgical FDA-approved imaging agent known as Gleolan Brain Dye/Aminolevulinic Acid HCI. The benefit of Gleolan is that it helps neurosurgeons to see “high grade gliomas”.

Navigating care for patients with cancer can be overwhelming considering the multiple specialists they encounter and the numerous decisions they must make. For patients with GBM management is further complicated by a poor prognosis, feelings of isolation, urgency to treat, and cognitive decline.

Join us in honoring brain cancer patients, families, friends, and caregivers. Support efforts to develop better treatments.

As a proud member of ASCO (American Society of Clinical Oncology), I am consistently impressed with the information they provide. They recently held their Annual Event I wanted to take the time to provide some of the incredible information and data that resulted from that meeting.

Groundbreaking news in the battle against brain cancer.It’s a response-prediction test which improves outcomes by testing live cancer cells against a number of potential therapies to demonstrate which ones will be most effective in killing the tumor cells.